Education
About Us
Working with TipRanks
Follow Us
Eupraxia Pharmaceuticals (EPRX)
NASDAQ:EPRX
EPRX Stock Chart & Stats
$8.46
-$0.02(-0.66%)
At close: 4:00 PM EST
$8.46
-$0.02(-0.66%)
Day’s Range― - ―
52-Week Range$2.68 - $9.32
Previous CloseN/A
Volume2.60K
Average Volume (3M)148.90K
Market Cap
C$448.83M
Enterprise Value$291.17M
Total Cash (Recent Filing)C$123.78M
Total Debt (Recent Filing)C$237.38K
Price to Earnings (P/E)―
Beta0.95
Next Earnings
Mar 31, 2026EPS Estimate
-0.14Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.20
Shares Outstanding50,648,330
10 Day Avg. Volume43,828
30 Day Avg. Volume148,898
Financial Highlights & Ratios
PEG Ratio0.13
Price to Book (P/B)4.58
Price to Sales (P/S)0.00
P/FCF Ratio-5.08
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
C$15.74Price Target Upside86.10% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical EfficacyAnalyst views RESOLVE data as showing substantial improvements in esophageal tissue health and high clinical remission rates after a single administration, indicating strong per-patient efficacy versus current therapies.
Dosing Convenience And DurabilityAnalyst notes sustained symptom improvement and a clear dose-response, suggesting EP-104GI could enable infrequent dosing and improve patient adherence compared with weekly biologics or daily steroid regimens.
Market Adoption PotentialSurvey feedback and key opinion leader alignment indicate strong physician appetite for EP-104GI and expectation that a meaningful share of topical steroid patients would switch if the product becomes available.
Bears Say
Candidiasis And Safety MonitoringReported rates of esophageal candidiasis in short-term studies raise safety concerns that may necessitate additional monitoring, patient counseling, or mitigation strategies before broad adoption.
Limited Physician FamiliarityOnly a minority of surveyed gastroenterologists reported strong familiarity with EP-104GI and recent clinical data, which could slow clinical uptake and commercial momentum.
Small Trial Cohorts And Statistical UncertaintyAnalyst warns that small cohort sizes in early RESOLVE data create uncertainty and that randomized, larger trials are required to confirm the observed efficacy and durability.
Eupraxia Pharmaceuticals News
EPRX FAQ
What was Eupraxia Pharmaceuticals’s price range in the past 12 months?
Eupraxia Pharmaceuticals lowest stock price was $2.68 and its highest was $9.32 in the past 12 months.
What is Eupraxia Pharmaceuticals’s market cap?
Eupraxia Pharmaceuticals’s market cap is C$448.83M.
When is Eupraxia Pharmaceuticals’s upcoming earnings report date?
Eupraxia Pharmaceuticals’s upcoming earnings report date is Mar 31, 2026 which is in 52 days.
How were Eupraxia Pharmaceuticals’s earnings last quarter?
Eupraxia Pharmaceuticals released its earnings results on Nov 04, 2025. The company reported -$0.196 earnings per share for the quarter, missing the consensus estimate of -$0.182 by -$0.014.
Is Eupraxia Pharmaceuticals overvalued?
According to Wall Street analysts Eupraxia Pharmaceuticals’s price is currently Undervalued.
Does Eupraxia Pharmaceuticals pay dividends?
Eupraxia Pharmaceuticals does not currently pay dividends.
What is Eupraxia Pharmaceuticals’s EPS estimate?
Eupraxia Pharmaceuticals’s EPS estimate is -0.14.
How many shares outstanding does Eupraxia Pharmaceuticals have?
Eupraxia Pharmaceuticals has 50,648,330 shares outstanding.
What happened to Eupraxia Pharmaceuticals’s price movement after its last earnings report?
Eupraxia Pharmaceuticals reported an EPS of -$0.196 in its last earnings report, missing expectations of -$0.182. Following the earnings report the stock price went up 4.037%.
Which hedge fund is a major shareholder of Eupraxia Pharmaceuticals?
Currently, no hedge funds are holding shares in EPRX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Eupraxia Pharmaceuticals Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
C$15.74 (86.10% Upside)
C$15.74 (86.10% Upside)
Insider Transactions
Bought Shares
Worth C$143.9K over
the Last 3 Months
the Last 3 Months
Technicals
SMA
Positive
20 days / 200 days
Momentum
134.00%
12-Months-Change
Fundamentals
Return on Equity
-158.24%
Trailing 12-Months
Asset Growth
-5.79%
Trailing 12-Months
Company Description
Eupraxia Pharmaceuticals
Eupraxia Pharmaceuticals Inc., a clinical stage biotechnology company, engages in the discovery, development, and marketing of technologies in the biotechnology sector. The company's lead product candidate is EP-104IAR, which is in a Phase II clinical trial for the treatment of unmet medical needs and for pain relief for knee osteoarthritis, as well as under development for treating canine and equine osteoarthritis. Its products in development also include EP-201, an antibiotic for post-surgical site infections; and EP-105, an extended-release post-surgical anesthetic for post-surgical pain. In addition, the company develops product candidates for oncology. The company was formerly known as Plaza Capital Partners Inc. and changed its name to Eupraxia Pharmaceuticals Inc. in May 2012.Eupraxia Pharmaceuticals Inc. was incorporated in 2011 and is headquartered in Victoria, Canada.
EPRX Stock 12 Month Forecast
Average Price Target
$15.74
▲(86.10% Upside)
Technical Analysis
NervGen Pharma
―
Entheon Biomedical
―
Bright Minds Biosciences
―
MYND Life Sciences
―
Mindbio Therapeutics Corp.
―
Ownership Overview
20.29% Insiders
0.02% Other Institutional Investors
79.69% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---